Section 5 of 6
Economic information and modeling report
36 evidence topics · 26 sources
Modeling overview
Summary: scope of the economic evidence
Envudeucitinib is an investigational drug. No cost-effectiveness, cost per responder, or budget impact analysis that includes envudeucitinib was found, and the report records no price for it. The evidence under this heading covers comparator prices from state, federal, and manufacturer sources; the 2016 and 2018 ICER assessments of targeted immunomodulators for plaque psoriasis; published cost-effectiveness, cost per responder, and budget impact analyses of comparators; and market statements by Alumis.
Summary: comparator prices by source
Prices are given as each source lists them, in U.S. dollars.
- Texas DSHS 2026 annual WAC report: Sotyktu 7135.55; TREMFYA 14566.44; TALTZ 7624.59; BIMZELX 160MG/ML auto-injector pen 8350.73; STELARA 29151.48 and 29151.46 (two NDCs); Otulfi 45 MG/0.5ML 1809.79; SELARSDI 45MG/0.5ML 2088.21; HUMIRA PEN 6922.62.
- California HCAI WAC increase file, January to October 2026: Otezla 30mg 60 pack and Otezla 75 mg extended-release 30 pack 5589.89 each (effective 01/07/2026); SKYRIZI PEN 150 mg 23838.42 (01/02/2026); COSENTYX 150 mg pen 8165.42 and 300 mg pen 8492.03 (01/07/2026); Enbrel Sureclick 50mg 4 pack 8565.48 (01/07/2026); SILIQ 210mg box of 2 syringes 6928.92 (05/11/2026); Cimzia 2 x 200 mg kit 6299.40 (01/01/2026).
- California HCAI new prescription drugs file: ICOTYDE 200mg tablet, package size 30, WAC at introduction 8285.0000 on 2026-03-18, with an estimated patient count of 8000000 in the filing.
- Department of Veterans Affairs Federal Supply Schedule, from 01/01/2026 unless noted: SOTYKTU 6MG TAB (30) FSS 6088.27 and Big Four 4815.81; OTEZLA 30MG TAB (60) 3495.82; OTEZLA XR 75MG TAB (30) 4775.29 from 01/29/2026; TREMFYA 100MG/ML 13931.32; SKYRIZI 150MG/ML 15522.22; STELARA 45MG/0.5ML 13980.15; ILUMYA 100MG/ML 11842.56; COSENTYX PEN (2 PENS) 6835.37; ENBREL 50MG/ML SURECLICK (4) 6933.40; HUMIRA 40MG/0.4ML (2) 5879.01.
- CMS Medicare Part B payment limits effective October 1, 2026 through December 31, 2026, based on 2Q26 ASP data, per 1 mg: tildrakizumab 120.965, guselkumab 66.998, risankizumab 14.011, intravenous secukinumab 18.131, intravenous ustekinumab 10.249, and certolizumab pegol 3.140; infliximab 29.856 per 10 mg.
- Medicare negotiation: the negotiated price for Otezla and Otezla XR (Amgen Inc.) is $1,650 for a 30-day supply in CY 2027, a 65% discount from the CY 2024 list price of $4,722; 31,000 Medicare Part D enrollees used the drug in CY 2024, with $1,045,443,000 in total Part D gross covered prescription drug costs. Cosentyx and Cimzia were selected for the third cycle of negotiation, with any negotiated prices effective beginning in 2028.
- Bristol Myers Squibb offers Sotyktu to eligible cash-pay U.S. patients through BMS Patient Connect, beginning January 2026, at more than 80% less than the current list price.
Summary: ICER assessments of targeted immunomodulators
- 2016 report: cost per QALY versus non-targeted therapy was $89,610 for apremilast, $89,843 for secukinumab, $92,715 for infliximab, $94,030 for brodalumab, $100,389 for ixekizumab, $108,040 for adalimumab, $117,769 for etanercept, and $129,904 for ustekinumab; results for brodalumab were tentative because pricing was not available. Using WAC prices, the ratios ranged from $140,000 to $187,000 per QALY gained. All drugs except adalimumab, apremilast, and infliximab required discounts from WAC to fall within the threshold range of $100,000 to $150,000/QALY. The candidate population, adults with moderate-to-severe plaque psoriasis taking a biologic agent for the first time, was approximately 36,750 incident cases per year; against a threshold of $904 million per year for 2015-16, the potential budgetary impact averaged approximately $239.8 million per year for brodalumab and approximately $266 million per year for ixekizumab.
- 2018 report: net prices for all drugs except infliximab were derived from SSR Health, LLC. The cost-effectiveness table gives cost per QALY versus non-targeted treatment from $131,000 for brodalumab to $188,000 for certolizumab pegol, with $135,000 for apremilast; the text gives the base-case range as $133-$188K/QALY and states that including productivity offsets lowered the ratios to $109-166K/QALY. At a $50K/QALY threshold no targeted drugs offered good value, and at a $100,000 per QALY threshold, initiation with brodalumab or infliximab each had a 10% probability of being optimal value. Annual discounts required to reach $100,000 per QALY ranged from 38% to 71%, and to reach $150,000 per QALY from 8% to 44%; for apremilast, the annual WAC was $40,000, the estimated net price $31,000, and the price to achieve $100,000 per QALY $17,500. The report states that IL-17 drug prices had increased since the 2016 report.
- 2018 budget impact: 29,342 incident cases of moderate-severe plaque psoriasis per year (approximately 146,710 over five years); at all prices except the price to reach $50,000 per QALY, the annual potential budgetary impact exceeded the threshold of $915 million, with an additional per-patient cost of approximately $58,900 at WAC and approximately $37,200 with the assumed discount.
Summary: cost-effectiveness and cost per responder analyses of comparators
- Hendrix et al.: in a 10-year Markov model with WAC discounted by a class-specific rebate percentage off 2016 costs, costs of care without targeted treatment totaled $66,451 and costs of targeted treatment ranged from $137,080 (apremilast) to $255,422 (ustekinumab); infliximab and apremilast were likely to be the most cost-effective initial treatments at thresholds around $100,000 per QALY, and IL-17 drugs at thresholds approaching $150,000 per QALY.
- Jia et al.: over 10 years, the incremental cost per QALY gained was lowest for brodalumab, infliximab, apremilast, and tildrakizumab.
- Kong and Buzney: mean annual total costs were $84,034 for biologics, $14,760 for office phototherapy, and $6222 for home phototherapy, with mean QALY gains of 0.24 for biologics, 0.18 for phototherapy, and 0.23 for step therapy.
- Egilman et al.: U.S. net prices of 13 biologic therapies ranged from $1664 to $79,277 per year, with a median net annual treatment cost of $34,965; U.S. prices would need a median reduction of 71% to align with efficiency frontier estimates.
- Park et al.: the cost per response of deucravacitinib versus apremilast was lower at 16 weeks (difference -$3796) and 24 weeks (difference -$12,784), and at 52 weeks the cost per cumulative benefit was lower for patients who initiated deucravacitinib.
- Wu et al. (cost per month with a PASI 75 response): the incremental cost per extra month with a PASI 75 response ranged from $3,685 for brodalumab to $13,476 for certolizumab pegol, with $4,770 for apremilast. Wu et al. (annual cost per response): the annual cost per PASI 75 was $48,782 for brodalumab and $87,243 for ustekinumab.
- Teeple and Muser and Teeple and Fitzgerald: the cost per PASI 90 response was $113,861 for guselkumab against $151,226 for adalimumab in the induction year, and $89,960 for guselkumab against $110,977 for secukinumab at 48 weeks.
- Blauvelt et al.: over 16 weeks, guselkumab had the lowest cost per cumulative benefit for PASI 90 ($99,742) and ixekizumab for PASI 100 ($230,884).
- McCoy et al.: NB-UVB had an adjusted monthly cost of $1714.00 per PASI 75, and infliximab, the least expensive biologic, $2076.00 to $2502.00.
Summary: published budget impact analyses of comparators
- Carrico et al.: a health plan of 1,000,000 members, with psoriasis prevalence of 3.2%, 90.0% with plaque psoriasis, 18.2% with moderate-to-severe disease, 20.0% treated with a biologic or apremilast, and 35.6% new users, had an estimated 1048 patients receiving biologics or apremilast. Adding tildrakizumab reduced total annual health plan cost by $5585 in year 1 and $342,563 in year 5, a cumulative $964,763 over 5 years, with per member per month reductions of $0.03 or less. Acquisition costs were based on WACs from May 2019.
- Feldman et al.: in a hypothetical commercial health plan of two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for brodalumab; the total annual pharmacy budget for biologics without brodalumab was $414,362,647, and brodalumab use of 3%, 8%, 16%, and 30% reduced it by $3,698,129, $9,861,677, $19,723,355, and $36,981,290.
Summary: market statements by Alumis
In its corporate presentation, Alumis describes psoriasis as a “Large marketplace with modest treatment penetration”, states that historical market share trends show a multi-winner market and that the uptake of Icotyde is largely additive, and reports that 84% of patients and 73% of dermatologists believe there is a need for better psoriasis therapies. In its annual report, Alumis states that the precise incidence and prevalence for the conditions it aims to address are unknown, that its estimates derive from sources including sales of competitors and market research and may prove to be incorrect, and that pricing of competitive products may limit the amount it will be able to charge for its product candidates, if approved.
Wholesale acquisition cost of deucravacitinib in the Texas 2026 annual report
| Field | Quoted value |
|---|---|
| Manufacturer | “Bristol-Myers Squibb Company” |
| Drug trade name | “Sotyktu” |
| Drug generic name | “deucravacitinib” |
| NDC11 | “3089511” |
| WAC price | “7135.55” |
Cash-pay offer for deucravacitinib through BMS Patient Connect beginning January 2026
Wholesale acquisition cost of icotrokinra at introduction in March 2026
| Field | Quoted value |
|---|---|
| Manufacturer | “Janssen Biotech, Inc.” |
| NDC | “57894020130” |
| Product description | “Strength: 200mg” |
| Product description, form and package | “Form: Tablet Package Size: 30” |
| Date introduced to market | “2026-03-18” |
| WAC at introduction | “8285.0000” |
| Estimated patients | “8000000” |
Eligible population stated by the manufacturer of icotrokinra in its California filing
Wholesale acquisition costs of apremilast and injectable biologics after 2026 increases
| Product | Drug product description | WAC effective date | WAC after increase |
|---|---|---|---|
| OTEZLA 30 mg | “Otezla, 30mg, Tablet, 60 pack” | “01/07/2026” | “5589.89” |
| OTEZLA XR 75 mg | “Otezla, 75 mg Tablet, Extended Release 25 HR, 30 pack” | “01/07/2026” | “5589.89” |
| SKYRIZI 150 mg pen | “SKYRIZI PEN PEN INJECTOR (ML) 150 mg/mL 1” | “01/02/2026” | “23838.42” |
| COSENTYX 150 mg pen | “COSENTYX PEN INJECTION SYRINGE 150 mg/mL 1” | “01/07/2026” | “8165.42” |
| COSENTYX 300 mg pen | “COSENTYX UNOREADY PEN INJECTION SYRINGE 300 mg/2 mL (150 mg/mL) 1” | “01/07/2026” | “8492.03” |
| ENBREL 50 mg autoinjector | “Enbrel Sureclick, 50mg/mL, Pen Injector (ML), 4 pack” | “01/07/2026” | “8565.48” |
| SILIQ 210 mg | “SILIQ™ (brodalumab) Injection 210mg/1.5mL (1 box of 2 syringes)” | “05/11/2026” | “6928.92” |
| CIMZIA 200 mg | “Cimzia prefilled syringe kit, 2 x 200 mg/ml prefilled syringes” | “01/01/2026” | “6299.40” |
Wholesale acquisition costs of injectable biologics and ustekinumab biosimilars in the Texas 2026 annual report
| Product | Drug trade name | NDC11 | WAC price |
|---|---|---|---|
| Guselkumab | “TREMFYA” | “57894064001” | “14566.44” |
| Ixekizumab | “TALTZ” | “2890511” | “7624.59” |
| Bimekizumab 160 mg | “BIMZELX 1 x 160MG/ML AUTO-INJECTOR PEN” | “50474078184” | “8350.73” |
| Ustekinumab | “STELARA” | “57894006003” | “29151.48” |
| Ustekinumab | “STELARA” | “57894006103” | “29151.46” |
| Ustekinumab-aauz 45 mg | “Otulfi Subcutaneous Solution Prefilled Syringe 45 MG/0.5ML” | “65219082401” | “1809.79” |
| Ustekinumab-aekn 45 mg | “SELARSDI PREFILLED SYRINGE 45MG/0.5ML 1” | “51759050532” | “2088.21” |
| Adalimumab | “HUMIRA PEN” | “74433902” | “6922.62” |
Federal Supply Schedule and Big Four prices for oral and injectable comparators
Medicare Part B payment limits for physician-administered biologics, fourth quarter of 2026
| Product | HCPCS code | Short description | HCPCS code dosage | Payment limit |
|---|---|---|---|---|
| Tildrakizumab | “J3245” | “Inj., tildrakizumab, 1 mg” | “1 MG” | “120.965” |
| Guselkumab | “J1628” | “Inj., guselkumab, 1 mg” | “1 MG” | “66.998” |
| Risankizumab | “J2327” | “Inj risankizumab-rzaa 1 mg” | “1 MG” | “14.011” |
| Certolizumab pegol | “J0717” | “Certolizumab pegol inj 1mg” | “1 MG” | “3.140” |
| Infliximab | “J1745” | “Infliximab not biosimil 10mg” | “10 MG” | “29.856” |
| Ustekinumab, intravenous | “J3358” | “Ustekinumab, iv inject, 1 mg” | “1 MG” | “10.249” |
| Secukinumab, intravenous | “J3247” | “Inj secukinumab intrav 1mg” | “1 MG” | “18.131” |
Medicare negotiated price for apremilast effective January 2027
| Field | Quoted value |
|---|---|
| Drug name | “Otezla; Otezla XR” |
| Participating drug company | “Amgen Inc.” |
| Agreed to negotiated price for 30-day supply for CY 2027 | “$1,650” |
| List price for 30-day supply, CY 2024 | “$4,722” |
| Discount of negotiated price from 2024 list price | “65%” |
| Total Part D gross covered prescription drug costs, CY 2024 | “$1,045,443,000” |
| Number of Medicare Part D enrollees who used the drug, CY 2024 | “31,000” |
Selection of secukinumab and certolizumab pegol for the third cycle of Medicare negotiation
| Drug name | Participating manufacturer |
|---|---|
| “Cimzia” | “UCB, Inc.” |
| “Cosentyx” | “Novartis Pharmaceuticals Corporation” |
Drug cost inputs and estimated net prices in the 2018 ICER assessment
| Intervention | Unit | WAC per unit or dose | Discount | Net price per unit | Cost of first year | Annual cost of year 2 and later |
|---|---|---|---|---|---|---|
| Adalimumab | “40 mg” | “$2,436.02” | “31%” | “$1,674.64” | “$46,751.16” | “$43,693.75” |
| Apremilast | “30 mg” | “$54.72” | “22%” | “$42.46” | “$30,807.28” | “$31,019.58” |
| Brodalumab | “210 mg” | “$1,750.00” | “20%” | “$1,400.00” | “$37,684.00” | “$36,528.00” |
| Certolizumab pegol | “400 mg” | “$4,044.32” | “36%” | “$2,583.70” | “$54,097.14” | “$50,559.32” |
| Etanercept | “50 mg” | “$1,218.00” | “31%” | “$837.69” | “$54,641.32” | “$43,713.06” |
| Guselkumab | “100 mg” | “$10,158.52” | “33%” | “$6,806.21” | “$50,609.02” | “$44,395.93” |
| Infliximab | “450 mg” | “$1,167.82” | “22%” | “$911.99” | “$38,466.44” | “$29,743.90” |
| Ixekizumab | “80 mg” | “$5,161.60” | “44%” | “$2,888.74” | “$51,374.18” | “$37,685.68” |
| Secukinumab | “300 mg” | “$4,712.38” | “38%” | “$2,926.22” | “$49,624.51” | “$38,174.63” |
Costs, QALYs, and cost per QALY of first-line targeted therapies in the 2018 ICER assessment
| First-line treatment | Total cost | Total QALYs | Cost per QALY versus non-targeted treatment | Cost per month in PASI 75 or better |
|---|---|---|---|---|
| Non-targeted treatment | “$67,800” | “5.70” | Not applicable | Not applicable |
| Adalimumab | “$308,000” | “7.17” | “$164,000” | “$3,200” |
| Apremilast | “$215,000” | “6.79” | “$135,000” | “$2,800” |
| Brodalumab | “$289,000” | “7.39” | “$131,000” | “$2,600” |
| Certolizumab pegol | “$341,000” | “7.16” | “$188,000” | “$3,700” |
| Etanercept | “$272,000” | “6.88” | “$175,000” | “$3,500” |
| Guselkumab | “$342,000” | “7.40” | “$161,000” | “$3,200” |
| Infliximab | “$238,000” | “6.98” | “$134,000” | “$2,700” |
| Ixekizumab | “$311,000” | “7.42” | “$142,000” | “$2,800” |
| Secukinumab | “$305,000” | “7.34” | “$145,000” | “$2,900” |
| Ustekinumab | “$315,000” | “7.17” | “$169,000” | “$3,300” |
Value-based price benchmarks in the 2018 ICER assessment
| Drug | Annual WAC | Annual estimated net price | Annual price to achieve $100,000 per QALY | Annual price to achieve $150,000 per QALY | Discount from WAC required to reach threshold prices |
|---|---|---|---|---|---|
| Adalimumab | “$63,600” | “$43,700” | “$25,700” | “$39,800” | “37% to 60%” |
| Apremilast | “$40,000” | “$31,000” | “$17,500” | “$36,600” | “8% to 56%” |
| Brodalumab | “$45,700” | “$36,500” | “$28,200” | “$41,500” | “9% to 38%” |
| Certolizumab pegol | “$79,100” | “$50,600” | “$25,500” | “$39,700” | “43% to 63%” |
| Etanercept | “$63,600” | “$43,700” | “$18,500” | “$35,400” | “44% to 71%” |
| Guselkumab | “$66,300” | “$44,400” | “$28,400” | “$41,500” | “37% to 57%” |
| Infliximab | “$38,100” | “$29,700” | “$18,800” | “$35,000” | “8% to 51%” |
| Ixekizumab | “$67,300” | “$37,700” | “$27,100” | “$39,700” | “41% to 60%” |
| Secukinumab | “$61,500” | “$38,200” | “$25,500” | “$39,400” | “36% to 59%” |
| Ustekinumab | “$58,200” | “$42,600” | “$25,200” | “$37,800” | “35% to 57%” |
| Risankizumab | Not available | Not available | “$27,300” | “$39,800” | Not available |
| Tildrakizumab | Not available | Not available | “$23,000” | “$36,800” | Not available |
Eligible population and potential budget impact in the 2018 ICER assessment
Base-case costs, QALYs, and cost per QALY in the 2016 ICER assessment
| Treatment | Cost | QALYs | Cost per QALY versus non-targeted therapy |
|---|---|---|---|
| Non-targeted therapy | “$88,086” | “5.531” | Not applicable |
| Adalimumab | “$208,881” | “6.649” | “$108,040” |
| Apremilast | “$161,741” | “6.353” | “$89,610” |
| Brodalumab | “$240,398” | “7.151” | “$94,030” |
| Etanercept | “$198,519” | “6.469” | “$117,769” |
| Infliximab | “$203,532” | “6.776” | “$92,715” |
| Ixekizumab | “$254,287” | “7.187” | “$100,389” |
| Secukinumab | “$221,704” | “7.018” | “$89,843” |
| Ustekinumab | “$269,843” | “6.930” | “$129,904” |
Value-based price benchmarks per unit in the 2016 ICER assessment
| Drug and unit | Net price | WAC | Cost to achieve $100,000 per QALY | Cost to achieve $150,000 per QALY | Discount from WAC to reach threshold |
|---|---|---|---|---|---|
| Adalimumab 40 mg | “$1,433.98” | “$2,048.54” | “$1,311.40” | “$2,073.74” | “36% to +1%” |
| Apremilast 30 mg | “$34.48” | “$43.10” | “$42.94” | “$83.64” | “0.4% to +94%” |
| Brodalumab 210 mg | “$2,560.07” | “$4,266.79” | “$2,696.61” | “$3,840.28” | “10% to 37%” |
| Etanercept 50 mg | “$717.11” | “$1,024.44” | “$566.68” | “$989.98” | “3% to 45%” |
| Infliximab 100 mg | “$779.24” | “$1,113.27” | “$857.54” | “$1,395.18” | “23% to +25%” |
| Ixekizumab 80 mg | “$2,681.40” | “$4,469” | “$2,672.66” | “$3,795.25” | “15% to 40%” |
| Secukinumab 300 mg | “$2,438.74” | “$4,064.57” | “$2,680.73” | “$3,872” | “5% to 34%” |
| Ustekinumab 45 mg | “$7,514.19” | “$8,840.22” | “$5,886.50” | “$8,608.05” | “3% to 33%” |
Eligible population and potential budget impact of brodalumab and ixekizumab in the 2016 ICER assessment
Ten-year cost-effectiveness of eight targeted therapies in a U.S. Markov model
“We developed a Markov model to simulate patient outcomes as measured by quality-adjusted life-years (QALYs) and health care costs over a 10-year period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Wholesale acquisition drug costs were discounted by a class-specific, empirically derived rebate percentage off of 2016 costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Costs of care without targeted treatment totaled $66,451, and costs of targeted treatment ranged from $137,080 (apremilast) to $255,422 (ustekinumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Probabilistic sensitivity analysis results indicated that infliximab and apremilast are likely to be the most cost-effective initial treatments at willingness-to-pay thresholds around $100,000 per QALY, while IL-17 drugs are more likely to be cost-effective at thresholds approaching $150,000 per QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of tildrakizumab and other first-line targeted therapies over 10 years
“Over 10 years, the incremental cost per QALY gained compared with a mix of topical therapies, phototherapies, and other oral systemic therapies was lowest for brodalumab, infliximab, apremilast, and tildrakizumab, followed by secukinumab, ixekizumab, guselkumab, adalimumab, ustekinumab, and etanercept.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The position of tildrakizumab relative to the other treatments remained the same across multiple scenarios.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A 10-year cost-effectiveness model was developed to compare the incremental cost per extra month with a Psoriasis Area and Severity Index (PASI) 75 response.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental cost per extra month a patient had a PASI 75 response was lowest for brodalumab ($3,685), infliximab ($4,102), apremilast ($4,770), and tildrakizumab ($5,150), followed by risankizumab ($5,319), secukinumab ($5,675), guselkumab ($5,784), ixekizumab ($5,900), adalimumab ($5,943), ustekinumab ($6,131), etanercept ($6,618), and certolizumab pegol ($13,476).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs and quality-adjusted life-years of biologics, phototherapy, and step therapy in a simulation model
“Simulation modeling study in patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index [PASI] ≥12) using published estimates of efficacy, costs, and mappings between PASI score and quality-adjusted life-years (QALYs) from 2013 through 2025.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) QALY gains were 0.24 (0.08) for biologics, 0.18 (0.09) for phototherapy, and 0.23 (0.06) for step therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean (SD) annual total costs were $84 034 (0) for biologics, $14 760 (0) for office phototherapy, and $6222 (0) for home phototherapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“From the payer perspective, mean (SD) net willingness to pay was highest for home phototherapy ($11 694 [$9421]) and lowest for biologics (-$59 926 [$7916]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among biologics, payers preferred adalimumab, whereas patients preferred bimekizumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
U.S. net prices of psoriasis biologics and price reductions under an efficiency frontier
“In this economic evaluation, US net prices of 13 biologic therapies for psoriasis ranged from $1664 to $79 277 per year, and clinical efficacy measured by Psoriasis Area Severity Index 90 scores ranged from 17.9% to 71.6%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (IQR) net annual treatment cost was higher in the US ($34 965 [$20 493-$48 942]) than prerebate costs in Australia ($9179 [$6691-$12 688]), Canada ($15 556 [$13 017-$16 112]), France ($9478 [$6637-$11 678]), and Germany ($13 829 [$13 231-$15 837]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“US prices for psoriasis biologics would need to be reduced by a median (IQR) of 71% (31%-95%) to align with those estimated using the EF; the same approach would yield smaller price reductions in Canada (41% [6%-57%]), Australia (36% [0%-65%]), France (19% [0%-67%]), and Germany (11% [8%-26%]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost per response of deucravacitinib and apremilast from a U.S. payer perspective
“A CPR model using pharmacy and administration costs was developed from a US payer perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The CPR for deucravacitinib versus apremilast was lower at 16 weeks (difference: -$3796 [95% confidence interval (CI): -$6140 to -$1659]) and 24 weeks (difference: -$12,784 [95% CI: -$16,674 to -$9369]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 52 weeks, the cost per cumulative benefit was lower for patients who initiated deucravacitinib, regardless of initial treatment period duration (16 or 24 weeks).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual cost per PASI 75, PASI 90, and PASI 100 response for five biologics
“Total annual costs to a health plan per patient with adalimumab, brodalumab, ixekizumab, secukinumab and ustekinumab were estimated at $51,246, $38,538, $65,484, $57,510 and $57,013.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean annual treatment costs per PASI 75, 90 and 100 were the lowest for brodalumab, with the annual cost per PASI 75 for brodalumab, adalimumab, ixekizumab, secukinumab and ustekinumab estimated at $48,782, $82,655, $77,957, $75,671 and $87,243, per PASI 90 at $51,383, $119,178, $94,904, $108,509 and $130,615, and per PASI 100 at $87,585, $284,702, $176,983, $205,393, and $366,645.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost per PASI 90 response for guselkumab in head-to-head trials with adalimumab and secukinumab
“The CPR for PASI 90 in the induction year for guselkumab was $113,861 vs $151,226 for adalimumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The NNT for a PASI 90 response was 1.3 for guselkumab and 2.1 for adalimumab; CPRs and NNT were also lower for guselkumab than for adalimumab for PASI 75 and PASI 100 for both induction and maintenance years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The CPR for PASI 90 response at 48 weeks was $89,960 for guselkumab versus $110,977 for secukinumab, and for the maintenance year it was $77,109 for guselkumab versus $88,781 for secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The NNT for a PASI 90 response was 1.18 for guselkumab and 1.43 for secukinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost per cumulative clinical benefit of seven biologics over 16 weeks
“Cost per cumulative benefit was estimated by multiplying number of doses (per FDA label) by nationally representative discounted wholesale acquisition costs (WACs) for 16 weeks of treatment divided by %Max_AUCW16.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the primary analysis, guselkumab had the lowest cost per cumulative benefit (95% credible interval [CrI]; $99,742 [$89,941-$111,653]), followed by ixekizumab ($108,906 [$95,928-$126,093]) and adalimumab ($111,233 [$97,549-$129,022]) for PASI 90, and ixekizumab had the lowest cost per cumulative benefit ($230,884 [$191,611-$291,115]), followed by secukinumab ($238,945 [$204,029-$288,072]) and risankizumab ($279,968 [$250,683-$316,872]) for PASI 100 responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Certolizumab pegol had the highest cost per cumulative benefit ($412,463 [$349,856-$499,199]) for PASI 90 response, and ustekinumab had the highest cost per cumulative benefit ($488,654 [$411,859-$601,642]) for PASI 100 response (Figure 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monthly cost per PASI 75 response of biologics and narrowband ultraviolet B phototherapy
“Phototherapy costs were estimated with Medicare fee schedules for phototherapy-related current procedural terminology code (CPT), and biologic costs were estimated with wholesale acquisition cost (WAC).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The psoriasis analysis found NB-UVB to be the most cost-effective therapy, with an adjusted monthly cost of $1714.00 per PASI 75.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Infliximab was the least expensive biologic, with an adjusted monthly cost of $2076.00 to $2502.00 per PASI 75.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact of adding tildrakizumab to a U.S. health plan of 1 million members
“The number of patients eligible for treatment was calculated from the US prevalence estimates for moderate-to-severe plaque psoriasis [1, 2, 4].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among all patients with moderate-to-severe plaque psoriasis, 20% were assumed to be treated with biologic treatments or apremilast [10], of whom 36% were estimated to be new to treatment due to incident psoriasis or switching between treatments [6, 7].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Population characteristic | Base case |
|---|---|
| Number of members in health plan | “1,000,000”View highlighted excerpt for this quote |
| Prevalence of psoriasis | “3.2%”View highlighted excerpt for this quote |
| Proportion with plaque psoriasis | “90.0%”View highlighted excerpt for this quote |
| Proportion with moderate-to-severe psoriasis | “18.2%”View highlighted excerpt for this quote |
| Proportion treated with a biologic or apremilast | “20.0%”View highlighted excerpt for this quote |
| New biologic or apremilast treatment users (require induction dosing) | “35.6%”View highlighted excerpt for this quote |
“Within a health plan of 1 million members with an estimated 1048 patients receiving biologics or apremilast for psoriasis, the total annual health plan cost after introducing tildrakizumab decreased by $5585, $137,025, $205,538, $274,051, and $342,563 in years 1–5, respectively, resulting in a cumulative reduction of $964,763 over 5 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental per member per month (PMPM) cost reductions were negligible in year 1, $0.01 in year 2, $0.02 in years 3–4, and $0.03 in year 5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Annual acquisition costs for biologic treatments and apremilast were based on wholesale acquisition costs (WACs) from May 2019 [11] and recommended dosing regimens from the corresponding prescribing information (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact of brodalumab on U.S. commercial health plans of 2 million members
“In a hypothetical commercial health plan covering two million members, 7,038 moderate-to-severe psoriasis patients were estimated to be eligible for treatment with brodalumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“When no brodalumab is used, the total annual pharmacy budget for the biologics used among these patients was estimated at $414,362,647.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among scenarios where the proportions of brodalumab usage were 3%, 8%, 16%, and 30%, the total annual pharmacy cost was estimated to be reduced by $3,698,129, $9,861,677, $19,723,355, and $36,981,290, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic analyses that include envudeucitinib
No evidence found.
Market size and treatment penetration stated by Alumis
Basis of Alumis market estimates and pricing constraints stated in its annual report
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.